| Popis: |
With platelet survival time (PST) determinations we observed in a group of 20 normal volunteers a platelet half life time (T½) of 99.05 hours. In a group of 35 patients with angina pectoris (A. P.) we obtained a T½ of 84.6 hours (p < 0.05).In a second trial on the effect of Clofibrate in patients with E. C. G. proven A. P., we obtained in 46 patients a T½ of 84.9 hours.The difference with the “normal” group was again significant (p < 0.02). When looking at patients with A. P. + hyperliporoteinaemie (HLP), we found in comparison with the “normal” group in A. P. + HLP type IIA: acc. to Frederickson: T½ = 96,7 (ns); in A. P. + HLP type IIB: T½ = 88.3 (p < 0.2), in A. P. + HLP type IV: T½ = 82.2 (p < 0,02).After 6 months treatment with Clofibrate or Placebo there was in the 27 A. P. treated with Clofebrate a significant increase in T½ of 106.8 hours (p < 0.01). In the group A. P. + HLP type IIB T½ = 90 (ns) and in the group A. P. + HLP type IV T½ = 94,3 (ns).In the 27 Clofibrate treated patients cholesterol level decreased from 257 mg% to 217 mg% (p < 0.001), the fibrinogen level from 397 mg% to 247 mg% (p < 0.001) and the ESR from 22 mm to 14,7 mm (p < 0.01). Results and possible explanations will be discussed. |
